

IMC-C103C

IMC-C103C, a T cell redirecting bi-specific biologic, IMC-C103C, an ImmTAC[®] molecule targeting tumours that express the protein MAGE-A4 (Melanoma-Associated Antigen A4) indicated multiple solid tumour indications NSCLC / Oesophageal / Gastric / Head & Neck / Bladder.

IMC-C103C as both monotherapy and in combination with atezolizumab (Tecentriq[®]). Genentech and Immunocore will now co-develop Immunocore's therapeutic candidate IMC-C103C, an ImmTAC[®] molecule targeting tumours that express the protein MAGE-A4 (Melanoma-Associated Antigen A4).

ImmTAC[®] (Immune mobilising monoclonal TCRs against cancer) molecules are a new class of bi-specific biologics designed to overcome the limitations of other immuno-oncology agents by combining a T cell receptor (TCR)-targeting system with an anti-CD3 effector function to activate a highly potent and specific T cell response to cancer cells.